Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical immunology"
DOI: 10.1016/j.clim.2021.108779
Abstract: CTLA4-haploinsufficiency is a complex disease of immune dysregulation presenting with a broad spectrum of clinical manifestations. CTLA4-Fc fusion proteins such as abatacept have been described to alleviate immune dysregulation in several adult cases of CTLA4-haploinsufficiency.… read more here.
Keywords: abatacept treatment; ctla4 haploinsufficiency; treatment refractory; haploinsufficiency ... See more keywords